Printer Friendly

ERSP reviews Prevoxin weight loss claims.

The Electronic Retailing Self-Regulation Program (ERSP), an investigative unit of the Council of Better Business Bureaus, has determined that National Weight Loss Institute (NWLI) can support general weight loss claims made in direct-response advertising for Prevoxin, a dietary supplement intended to promote weight loss, but recommended the marketer modify or discontinue certain claims.

Following its review of the case record, ERSP determined that the two clinical human studies on 3-acetyl-7-oxo-dehydro-epiandrosterone, or 7-Keto DHEA, provided reliable support for the marketer's establishment claim of 200% increased weight loss when using the product in combination with diet and exercise. However, ERSP found the evidence did not provide adequate substantiation for the claim that Prevoxin can help users" lose 3x as much body fat."

Regarding claims pertaining to the "pharmaceutical quality" of Prevoxin, ERSP recommended that NWLI clearly present the related disclosure independently of the disclosure that qualifies weight loss results in order to prevent any ambiguity.

ERSP also recommended the marketer discontinue the testimonial in question, as the relevant disclosure did not adequately convey the results consumers can generally expect to achieve from use of the product.
COPYRIGHT 2013 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Industry News
Publication:Nutraceuticals World
Date:Mar 1, 2013
Previous Article:NPF's Truth in Advertising Program marks third year.
Next Article:Natac adopts olive through ABC program.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |